查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1656902

经皮药物输送设备:市场洞察·竞争情形·市场预测 (～2032年)

Transdermal Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

透皮给药装置市场规模预计将从 2024 年的 71,566,270 百万美元增长到 2032 年的 121,798,760 百万美元，预测期内的复合年增长率为 6.91%。

慢性病盛行率的不断上升和第三代透皮给药装置的日益普及，极大地促进了此类装置的全球市场的发展。技术进步提高了设备的效率，改善了药物吸收并方便了患者。此外，它在荷尔蒙失调、心血管疾病、疼痛管理和其他领域的多种应用，提供非侵入性、可控和患者友好的药物传输选择，进一步推动了需求。这些因素共同推动了 2025-2032 年预测期内透皮给药装置的使用和发展在全球范围内的扩大。

根据类型，含药贴片部分预计将在 2024 年占据市场主导地位，占有率为 55.44%。预计在预测期内，这些黏性贴片所提供的各种好处和应用将推动其需求。含药黏性透皮贴片是一种药物输送系统，旨在透过皮肤将药物输送到血液中。这些贴片旨在随着时间推移释放药物，提供可控且一致的治疗剂量。黏合层有助于将贴片黏附在皮肤上，并控制药物释放的速度。一旦将贴片贴到皮肤上，药物就会逐渐透过皮肤扩散到血液中，随着时间的推移，药物会稳定且可控地释放。

按地区划分，预计北美将在 2024 年占据最大占有率，为 45.39%，并在预测期内以 5.91% 的复合年增长率增长。这被认为是由于该地区慢性疼痛、中枢神经系统疾病和心血管疾病等目标疾病的盛行率不断增加、新产品的推出以及对研发活动的重视程度而不断提高。

本报告提供全球经皮药物输送设备的市场调查，彙整市场概要，市场影响因素及市场机会分析，法律制度，市场规模的转变·预测，各种区分·地区/各主要国家的详细分析，竞争情形，主要企业简介等资讯。

目录

第1章 经皮药物输送设备市场报告:简介

  • 调查范围
  • 市场区隔
  • 市场前提条件

第2章 经皮药物输送设备市场:摘要整理

  • 市场概要

第3章 竞争情形

第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 经皮药物输送设备市场:主要要素分析

  • 推动市场要素
    • 慢性病发生率上升
    • 第三代透皮给药装置的采用日益广泛
    • 科技进步日新月异
    • 全球范围内设备的使用日益广泛：从荷尔蒙失调到心血管疾病再到疼痛管理
  • 市场限制与课题
    • 与透皮给药装置相关的限制（例如应用部位的刺激和肿胀）
    • 增加产品召回
  • 市场机会
    • 提高对透皮给药装置的认识
    • 越来越多的患者采用无痛透皮给药装置

第6章 经皮药物输送设备市场:波特的五力分析

第7章 经皮药物输送设备市场评估

  • 各类型
    • 含药贴剂
    • 矩阵补丁
    • 储库膜贴片
    • 微针贴片
  • 各用途
    • 疼痛管理
    • 中枢神经系统疾病
    • 荷尔蒙
    • 心血管疾病
    • 其他
  • 各终端用户
    • 医院
    • 门诊病人手术中心
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 经皮药物输送设备市场:企业·产品简介

  • Novartis
  • Viatris Inc.
  • UCB SA
  • Hisamitsu Pharmaceutical
  • Boehringer Ingelheim
  • Johnson & Johnson Services Inc.
  • Purdue Pharma
  • Bayer AG
  • Haleon Group of Companies
  • Ingenus Pharmaceuticals
  • Luye Pharma Group
  • Cumberland Pharmaceuticals Inc.
  • Sanofi
  • Sparsha Pharma International Pvt Ltd.
  • Cipla

第9章 KOL的见解

第10章 计划的方法

第11章 关于DelveInsight

第12章 免责声明·联络方式

Product Code: DIMDCL0048

Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic conditions, increase in adoption of third-generation transdermal drug delivery devices, technological advancements observed in the device, and use of these devices from hormonal disorders to cardiovascular conditions and pain management across the globe.

The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032. The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.

Transdermal Drug Delivery Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases.

Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women are affected. Additionally, around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed. As the prevalence of CVDs rises globally, particularly among aging populations and individuals with sedentary lifestyles, the need for convenient, long-term treatment solutions has intensified. Thus, transdermal drug delivery devices allow for controlled and consistent delivery of medications like antihypertensives, antianginal drugs, and anticoagulants, ensuring better therapeutic outcomes and improved patient compliance thereby boosting the overall market across the globe.

Additionally, as per the recent data provided by the World Health Organization (2024), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally. Thus, with the rising prevalence of neurological disorders, there is a growing demand for non-invasive and effective treatment methods. These transdermal drug delivery devices provide controlled and consistent delivery of medications, bypassing the gastrointestinal tract and reducing side effects often associated with oral or injectable therapies thereby boosting the market of transdermal drug delivery devices across the globe.

Additionally, the increase in strategic activities among the key market players is further boosting the market of transdermal drug delivery devices across the globe. For instance, in January 2024, Starton Therapeutics announced the launch of STARSILON a novel proprietary transdermal patch delivery platform.

Thus, the factors mentioned above are expected to boost the overall market of transdermal drug delivery devices across the globe during the forecast period from 2025 to 2032.

However, disadvantages associated with transdermal drug delivery devices such as irritation at the site of application edema and increased product recalls may hinder the future market of transdermal drug delivery devices across the globe during the forecasted period.

Transdermal Drug Delivery Devices Market Segment Analysis:

Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The drug-in-adhesive patches category in the transdermal drug delivery devices market is estimated to dominate the market with a market share of 55.44% in 2024. This can be attributed to the various advantages and applications provided by these adhesive patches which will be responsible for driving the demand for transdermal drug delivery devices market during the given forecast period. Drug-in-adhesive transdermal patches are a type of drug delivery system designed to deliver drugs through the skin and into the bloodstream. These patches are designed to release the drug over time, providing a controlled and consistent therapeutic dosage. The adhesive layer adheres the patch to the skin and also helps to control the rate at which the drug is released. When the patch is applied to the skin, the drug gradually diffuses through the skin and into the bloodstream, providing a steady and controlled release of medication over time.

Drug-in-adhesive transdermal patches are easy to apply and do not require needles or invasive procedures, making them more convenient and patient-friendly. These drug delivery systems provide a controlled and consistent release of medication over a prolonged period, which helps to maintain stable drug levels in the bloodstream. Further presence of some key products in the market such as TRANSDERM-V by Novartis and Mylan-rivastigmine Patch 10 by Viatris Inc. will also contribute in propelling the growth of this category.

Hence, owing to the above-mentioned factors, the market for drug-in-adhesive will experience increased demand, thus driving the overall transdermal drug delivery devices market during the forecast period.

North America is expected to dominate the overall transdermal drug delivery devices market:

Among all regions, North America is estimated to hold the largest share of 45.39% in the global transdermal drug delivery devices market in 2024, growing at a CAGR of 5.91% during the forecast period from 2025 to 2032. This can be attributed to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.

According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

Additionally, as per the recent data provided by the Alzheimer's Association, in 2024, approximately 6.9 million Americans age 65 and older are living with Alzheimer's. Furthermore, as per the recent data provided by the Parkinson's Foundation (2022), nearly 90,000 people are diagnosed with Parkinson's disease in the U.S. each year and approximately one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Thus, the rising prevalence of these diseases, coupled with the demand for patient-friendly solutions that improve adherence and reduce systemic side effects, is accelerating the adoption of transdermal technologies.

Furthermore, the increasing number of product development activities in the region is further going to accelerate the growth of the spinal non-fusion devices market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG announced the launch of the UDENYCA(R) on-body injector (OBI) through its Sorrel(TM) platform. UDENYCA(R) (pegfilgrastim-cbqv) aims to reduce infection risks post-chemotherapy. The FDA approved the device in December 2023, enhancing patient convenience and drug administration at home.

Thus, the above-mentioned factors are expected to escalate the market of transdermal drug delivery devices in the region.

Transdermal Drug Delivery Devices Market Key Players:

Some of the key market players operating in the transdermal drug delivery devices market include Novartis, Viatris Inc., UCB SA, Hisamitsu Pharmaceutical, Boehringer Ingelheim, Johnson & Johnson Services Inc., Purdue Pharma, Bayer AG, Haleon Group of Companies, Ingenus Pharmaceuticals, Luye Pharma Group, Cumberland Pharmaceuticals Inc., Sanofi, Sparsha Pharma International Pvt Ltd., Cipla, and others.

Recent Developmental Activities in the Transdermal Drug Delivery Devices Market:

  • In July 2024, Kindeva Drug Delivery's Woodbury, MN facility was FDA-inspected and classified. The facility now supports clients with integrated and stand-alone analytical services for pharmaceutical, biopharmaceutical, and medical device sectors.
  • In March 2024, PassPort Technologies, Inc., a San Diego-based clinical-stage company, reported positive interim results from its Phase 1 trial of Zolmitriptan PassPort(R), using a proprietary transdermal microporation system for acute migraine treatment. Zolmitriptan, an FDA-approved migraine medication, is tested for efficacy via this new delivery system.

Key Takeaways From the Transdermal Drug Delivery Devices Market Report Study

  • Market size analysis for current transdermal drug delivery devices size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the transdermal drug delivery devices market.
  • Various opportunities available for the other competitors in the transdermal drug delivery devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current transdermal drug delivery devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for transdermal drug delivery devices market growth in the coming future?

Target Audience Who Can be Benefited From This Transdermal Drug Delivery Devices Market Report Study

  • Transdermal drug delivery devices product providers
  • Research organizations and consulting companies
  • Transdermal Drug Delivery Devices -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in transdermal drug delivery devices
  • Various end-users who want to know more about the transdermal drug delivery devices market and the latest technological developments in the transdermal drug delivery devices market.

Frequently Asked Questions for the Transdermal Drug Delivery Devices Market:

1. What are transdermal drug delivery devices?

  • Transdermal drug delivery (TDD) is a method that delivers drugs through the skin for controlled, sustained release over time. It improves patient compliance and avoids first-pass metabolism in the liver, providing an appealing alternative to oral and hypodermic drug administration.

2. What is the market for transdermal drug delivery devices?

  • The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032.

3. What are the drivers for the global transdermal drug delivery devices market?

  • The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global transdermal drug delivery devices market?

  • Some of the key market players operating in the transdermal drug delivery devices are Novartis, Viatris Inc., UCB SA, Hisamitsu Pharmaceutical, Boehringer Ingelheim, Johnson & Johnson Services Inc., Purdue Pharma, Bayer AG, Haleon Group of Companies, Ingenus Pharmaceuticals, Luye Pharma Group, Cumberland Pharmaceuticals Inc., Sanofi, Sparsha Pharma International Pvt Ltd., Cipla, and others.

5. Which region has the highest share in the global transdermal drug delivery devices market?

  • North America region is anticipated to dominate the overall transdermal drug delivery devices market due to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.

Table of Contents

1. Transdermal Drug Delivery Devices Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Transdermal Drug Delivery Devices Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Transdermal Drug Delivery Devices Market Key Factors Analysis

  • 5.1. Transdermal Drug Delivery Devices Market Drivers
    • 5.1.1. The increasing prevalence of chronic conditions
    • 5.1.2. Increase in adoption of third-generation transdermal drug delivery devices
    • 5.1.3. Increase in the technological advancements
    • 5.1.4. Increase use of these devices for hormonal disorders to cardiovascular conditions and pain management across the globe
  • 5.2. Transdermal Drug Delivery Devices Market Restraints and Challenges
    • 5.2.1. Limitation associated with transdermal drug delivery devices such as irritation at site of application and edema
    • 5.2.2. Increase product recalls
  • 5.3. Transdermal Drug Delivery Devices Market Opportunities
    • 5.3.1. Increasing awareness towards transdermal drug delivery devices
    • 5.3.2. Increased patient adoption for pain-less transdermal drug delivery devices

6. Transdermal Drug Delivery Devices Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Transdermal Drug Delivery Devices Market Assessment

  • 7.1. By Type
    • 7.1.1. Drug-in-adhesive Patches
    • 7.1.2. Matrix Patches
    • 7.1.3. Reservoir Membrane Patches
    • 7.1.4. Microneedle Patches
  • 7.2. By Application
    • 7.2.1. Pain Management
    • 7.2.2. Central Nervous System Disorders
    • 7.2.3. Hormonal Applications
    • 7.2.4. Cardiovascular Disorders
    • 7.2.5. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Ambulatory Surgical Centers
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.1.2. Canada Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.1.3. Mexico Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.2. Germany Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.3. United Kingdom Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.4. Italy Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.5. Spain Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.6. Rest of Europe Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.2. Japan Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.3. India Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.4. Australia Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.5. South Korea Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.4.2. Africa Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.4.3. South America Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)

8. Transdermal Drug Delivery Devices Market Company and Product Profiles

  • 8.1. Novartis
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Viatris Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. UCB SA
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Hisamitsu Pharmaceutical
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Boehringer Ingelheim
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Johnson & Johnson Services Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Purdue Pharma
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Bayer AG
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Haleon Group of Companies
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Ingenus Pharmaceuticals
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Luye Pharma Group
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Cumberland Pharmaceuticals Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Sanofi
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Sparsha Pharma International Pvt Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Cipla
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Transdermal Drug Delivery Devices Market in Global (2022-2032)
  • Table 3: Transdermal Drug Delivery Devices Market in Global by Type (2022-2032)
  • Table 4: Transdermal Drug Delivery Devices Market in Global by Application (2022-2032)
  • Table 5: Transdermal Drug Delivery Devices Market in Global by End-User (2022-2032)
  • Table 6: Transdermal Drug Delivery Devices Market in Global by Geography (2022-2032)
  • Table 7: Transdermal Drug Delivery Devices Market in North America (2022-2032)
  • Table 8: Transdermal Drug Delivery Devices Market in the United States (2022-2032)
  • Table 9: Transdermal Drug Delivery Devices Market in Canada (2022-2032)
  • Table 10: Transdermal Drug Delivery Devices Market in Mexico (2022-2032)
  • Table 11: Transdermal Drug Delivery Devices Market in Europe (2022-2032)
  • Table 12: Transdermal Drug Delivery Devices Market in France (2022-2032)
  • Table 13: Transdermal Drug Delivery Devices Market in Germany (2022-2032)
  • Table 14: Transdermal Drug Delivery Devices Market in the United Kingdom (2022-2032)
  • Table 15: Transdermal Drug Delivery Devices Market in Italy (2022-2032)
  • Table 16: Transdermal Drug Delivery Devices Market in Spain (2022-2032)
  • Table 17: Transdermal Drug Delivery Devices Market in the Rest of Europe (2022-2032)
  • Table 18: Transdermal Drug Delivery Devices Market in Asia-Pacific (2022-2032)
  • Table 19: Transdermal Drug Delivery Devices Market in China (2022-2032)
  • Table 20: Transdermal Drug Delivery Devices Market in Japan (2022-2032)
  • Table 21: Transdermal Drug Delivery Devices Market in India (2022-2032)
  • Table 22: Transdermal Drug Delivery Devices Market in Australia (2022-2032)
  • Table 23: Transdermal Drug Delivery Devices Market in South Korea (2022-2032)
  • Table 24: Transdermal Drug Delivery Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Transdermal Drug Delivery Devices Market in the Rest of the World (2022-2032)
  • Table 26: Transdermal Drug Delivery Devices Market in the Middle East (2022-2032)
  • Table 27: Transdermal Drug Delivery Devices Market in Africa (2022-2032)
  • Table 28: Transdermal Drug Delivery Devices Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Transdermal Drug Delivery Devices Market in Global (2022-2032)
  • Figure 3: Transdermal Drug Delivery Devices Market in Global by Type (2022-2032)
  • Figure 4: Transdermal Drug Delivery Devices Market in Global by Application (2022-2032)
  • Figure 5: Transdermal Drug Delivery Devices Market in Global by End-User (2022-2032)
  • Figure 6: Transdermal Drug Delivery Devices Market in Global by Geography (2022-2032)
  • Figure 7: Transdermal Drug Delivery Devices Market in North America (2022-2032)
  • Figure 8: Transdermal Drug Delivery Devices Market in the United States (2022-2032)
  • Figure 9: Transdermal Drug Delivery Devices Market in Canada (2022-2032)
  • Figure 10: Transdermal Drug Delivery Devices Market in Mexico (2022-2032)
  • Figure 11: Transdermal Drug Delivery Devices Market in Europe (2022-2032)
  • Figure 12: Transdermal Drug Delivery Devices Market in France (2022-2032)
  • Figure 13: Transdermal Drug Delivery Devices Market in Germany (2022-2032)
  • Figure 14: Transdermal Drug Delivery Devices Market in the United Kingdom (2022-2032)
  • Figure 15: Transdermal Drug Delivery Devices Market in Italy (2022-2032)
  • Figure 16: Transdermal Drug Delivery Devices Market in Spain (2022-2032)
  • Figure 17: Transdermal Drug Delivery Devices Market in the Rest of Europe (2022-2032)
  • Figure 18: Transdermal Drug Delivery Devices Market in Asia-Pacific (2022-2032)
  • Figure 19: Transdermal Drug Delivery Devices Market in China (2022-2032)
  • Figure 20: Transdermal Drug Delivery Devices Market in Japan (2022-2032)
  • Figure 21: Transdermal Drug Delivery Devices Market in India (2022-2032)
  • Figure 22: Transdermal Drug Delivery Devices Market in Australia (2022-2032)
  • Figure 23: Transdermal Drug Delivery Devices Market in South Korea (2022-2032)
  • Figure 24: Transdermal Drug Delivery Devices Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Transdermal Drug Delivery Devices Market in the Rest of the World (2022-2032)
  • Figure 26: Transdermal Drug Delivery Devices Market in the Middle East (2022-2032)
  • Figure 27: Transdermal Drug Delivery Devices Market in Africa (2022-2032)
  • Figure 28: Transdermal Drug Delivery Devices Market in South America (2022-2032)
  • Figure 29: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Market Opportunities
  • Figure 32: PORTER'S Five Force Analysis